journal
MENU ▼
Read by QxMD icon Read
search

Breast Cancer Research: BCR

journal
https://www.readbyqxmd.com/read/29769144/contributions-of-the-rhoa-guanine-nucleotide-exchange-factor-net1-to-polyoma-middle-t-antigen-mediated-mammary-gland-tumorigenesis-and-metastasis
#1
Yan Zuo, Arzu Ulu, Jeffrey T Chang, Jeffrey A Frost
BACKGROUND: The RhoA activating protein Net1 contributes to breast cancer cell proliferation, motility, and invasion in vitro, yet little is known about its roles in mammary gland tumorigenesis and metastasis. METHODS: Net1 knockout (KO) mice were bred to mice with mammary gland specific expression of the polyoma middle T antigen (PyMT) oncogene. Mammary gland tumorigenesis and lung metastasis were monitored. Individual tumors were assessed for proliferation, apoptosis, angiogenesis, RhoA activation, and activation of PyMT-dependent signaling pathways...
May 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29769099/circulating-esr1-mutations-at-the-end-of-aromatase-inhibitor-adjuvant-treatment-and-after-relapse-in-breast-cancer-patients
#2
Violette Allouchery, Ludivine Beaussire, Anne Perdrix, David Sefrioui, Laetitia Augusto, Cécile Guillemet, Nasrin Sarafan-Vasseur, Frédéric Di Fiore, Florian Clatot
BACKGROUND: Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence of circulating ESR1 mutations at the end of adjuvant treatment by AI in early breast cancer had never been clearly established. In this context, the aim of the present study was to evaluate the circulating ESR1 mutation frequency at the end of adjuvant treatment and after relapse. METHODS: This monocentric retrospective study was based on available stored plasmas and included all early breast cancer patients who completed at least 2 years of AI adjuvant treatment and experienced a documented relapse after the end of their treatment...
May 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29720233/real-world-evidence-analysis-of-palbociclib-prescribing-patterns-for-patients-with-advanced-metastatic-breast-cancer-treated-in-community-oncology-practice-in-the-usa-one-year-post-approval
#3
J K Kish, M A Ward, D Garofalo, H V Ahmed, L McRoy, J Laney, G Zanotti, J Braverman, H Yu, B A Feinberg
BACKGROUND: Rapidly evolving understanding of cancer biology has presented novel opportunities to translate that understanding into clinically relevant therapy. Palbociclib, a novel, first-in-class cyclin-dependent kinase (CDK) 4/6 inhibitor was approved in the USA in February 2015 for the treatment of advanced/metastatic breast cancer. We examined real-world evidence in the first year post approval to understand the clinical and demographic characteristics of patients treated with palbociclib in community oncology practices and the dosing, treatment, and complete blood count (CBC) monitoring patterns...
May 2, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29720224/assessing-brain-volume-changes-in-older-women-with-breast-cancer-receiving-adjuvant-chemotherapy-a-brain-magnetic-resonance-imaging-pilot-study
#4
Bihong T Chen, Sean K Sethi, Taihao Jin, Sunita K Patel, Ningrong Ye, Can-Lan Sun, Russell C Rockne, E Mark Haacke, James C Root, Andrew J Saykin, Tim A Ahles, Andrei I Holodny, Neal Prakash, Joanne Mortimer, James Waisman, Yuan Yuan, George Somlo, Daneng Li, Richard Yang, Heidi Tan, Vani Katheria, Rachel Morrison, Arti Hurria
BACKGROUND: Cognitive decline is among the most feared treatment-related outcomes of older adults with cancer. The majority of older patients with breast cancer self-report cognitive problems during and after chemotherapy. Prior neuroimaging research has been performed mostly in younger patients with cancer. The purpose of this study was to evaluate longitudinal changes in brain volumes and cognition in older women with breast cancer receiving adjuvant chemotherapy. METHODS: Women aged ≥ 60 years with stage I-III breast cancer receiving adjuvant chemotherapy and age-matched and sex-matched healthy controls were enrolled...
May 2, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29720220/the-combined-effect-of-mammographic-texture-and-density-on-breast-cancer-risk-a-cohort-study
#5
Johanna O P Wanders, Carla H van Gils, Nico Karssemeijer, Katharina Holland, Michiel Kallenberg, Petra H M Peeters, Mads Nielsen, Martin Lillholm
BACKGROUND: Texture patterns have been shown to improve breast cancer risk segregation in addition to area-based mammographic density. The additional value of texture pattern scores on top of volumetric mammographic density measures in a large screening cohort has never been studied. METHODS: Volumetric mammographic density and texture pattern scores were assessed automatically for the first available digital mammography (DM) screening examination of 51,400 women (50-75 years of age) participating in the Dutch biennial breast cancer screening program between 2003 and 2011...
May 2, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29720215/dependence-receptor-unc5a-restricts-luminal-to-basal-breast-cancer-plasticity-and-metastasis
#6
Maria B Padua, Poornima Bhat-Nakshatri, Manjushree Anjanappa, Mayuri S Prasad, Yangyang Hao, Xi Rao, Sheng Liu, Jun Wan, Yunlong Liu, Kyle McElyea, Max Jacobsen, George Sandusky, Sandra Althouse, Susan Perkins, Harikrishna Nakshatri
BACKGROUND: The majority of estrogen receptor-positive (ERα+ ) breast cancers respond to endocrine therapies. However, resistance to endocrine therapies is common in 30% of cases, which may be due to altered ERα signaling and/or enhanced plasticity of cancer cells leading to breast cancer subtype conversion. The mechanisms leading to enhanced plasticity of ERα-positive cancer cells are unknown. METHODS: We used short hairpin (sh)RNA and/or the CRISPR/Cas9 system to knockdown the expression of the dependence receptor UNC5A in ERα+ MCF7 and T-47D cell lines...
May 2, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29720211/atypical-ductal-hyperplasia-update-on-diagnosis-management-and-molecular-landscape
#7
REVIEW
Tanjina Kader, Prue Hill, Emad A Rakha, Ian G Campbell, Kylie L Gorringe
BACKGROUND: Atypical ductal hyperplasia (ADH) is a common diagnosis in the mammographic era and a significant clinical problem with wide variation in diagnosis and treatment. After a diagnosis of ADH on biopsy a proportion are upgraded to carcinoma upon excision; however, the remainder of patients are overtreated. While ADH is considered a non-obligate precursor of invasive carcinoma, the molecular taxonomy remains unknown. MAIN TEXT: Although a few studies have revealed some of the key genomic characteristics of ADH, a clear understanding of the molecular changes associated with breast cancer progression has been limited by inadequately powered studies and low resolution methodology...
May 2, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29669595/imp1-regulates-uca1-mediated-cell-invasion-through-facilitating-uca1-decay-and-decreasing-the-sponge-effect-of-uca1-for-mir-122-5p
#8
Yanchun Zhou, Xiuhua Meng, Shaoying Chen, Wei Li, Delin Li, Robert Singer, Wei Gu
BACKGROUND: Long noncoding RNAs (LncRNAs) represent a class of widespread and diverse endogenous RNAs that can posttranscriptionally regulate gene expression through the interaction with RNA-binding proteins and micro RNAs (miRNAs). Here, we report that in breast carcinoma cells, the insulin-like growth factor 2 messenger RNA binding protein (IMP1) binds to lncRNA urethral carcinoma-associated 1 (UCA1) and suppresses the UCA1-induced invasive phenotype. METHODS: RT-qPCR and RNA sequence assays were used to investigate the expression of UCA1 and miRNAs in breast cancer cells in response to IMP1 expression...
April 18, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29669587/comparison-of-methods-to-assess-onset-of-breast-development-in-the-legacy-girls-study-methodological-considerations-for-studies-of-breast-cancer
#9
Lauren C Houghton, Julia A Knight, Mary Jane De Souza, Mandy Goldberg, Melissa L White, Karen O'Toole, Wendy K Chung, Angela R Bradbury, Mary B Daly, Irene L Andrulis, Esther M John, Saundra S Buys, Mary Beth Terry
BACKGROUND: Younger age at onset of breast development, which has been declining in recent decades, is associated with increased breast cancer risk independent of age at menarche. Given the need to study the drivers of these trends, it is essential to validate methods to assess breast onset that can be used in large-scale studies when direct clinical assessment of breast onset is not feasible. METHODS: Breast development is usually measured by Tanner stages (TSs), assessed either by physical examination or by mother's report using a picture-based Sexual Maturation Scale (SMS)...
April 18, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29669584/mri-based-response-patterns-during-neoadjuvant-chemotherapy-can-predict-pathological-complete-response-in-patients-with-breast-cancer
#10
Briete Goorts, Kelly M A Dreuning, Janneke B Houwers, Loes F S Kooreman, Evert-Jan G Boerma, Ritse M Mann, Marc B I Lobbes, Marjolein L Smidt
BACKGROUND: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability. METHODS: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included...
April 18, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29669579/long-term-prognostic-implications-of-risk-factors-associated-with-tumor-size-a-case-study-of-women-regularly-attending-screening
#11
Fredrik Strand, Keith Humphreys, Johanna Holm, Mikael Eriksson, Sven Törnberg, Per Hall, Edward Azavedo, Kamila Czene
BACKGROUND: Breast cancer prognosis is strongly associated with tumor size at diagnosis. We aimed to identify factors associated with diagnosis of large (> 2 cm) compared to small tumors, and to examine implications for long-term prognosis. METHODS: We examined 2012 women with invasive breast cancer, of whom 1466 had screen-detected and 546 interval cancers that were incident between 2001 and 2008 in a population-based screening cohort, and followed them to 31 December 2015...
April 18, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29665866/mitochondrial-dna-copy-number-variation-leukocyte-telomere-length-and-breast-cancer-risk-in-the-european-prospective-investigation-into-cancer-and-nutrition-epic-study
#12
Daniele Campa, Myrto Barrdahl, Aurelia Santoro, Gianluca Severi, Laura Baglietto, Hanane Omichessan, Rosario Tumino, H B As Bueno-de-Mesquita, Petra H Peeters, Elisabete Weiderpass, Maria-Dolores Chirlaque, Miguel Rodríguez-Barranco, Antonio Agudo, Marc Gunter, Laure Dossus, Vittorio Krogh, Giuseppe Matullo, Antonia Trichopoulou, Ruth C Travis, Federico Canzian, Rudolf Kaaks
BACKGROUND: Leukocyte telomere length (LTL) and mitochondrial genome (mtDNA) copy number and deletions have been proposed as risk markers for various cancer types, including breast cancer (BC). METHODS: To gain a more comprehensive picture on how these markers can modulate BC risk, alone or in conjunction, we performed simultaneous measurements of LTL and mtDNA copy number in up to 570 BC cases and 538 controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort...
April 17, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29665859/morphology-and-genomic-hallmarks-of-breast-tumours-developed-by-atm-deleterious-variant-carriers
#13
Anne-Laure Renault, Noura Mebirouk, Laetitia Fuhrmann, Guillaume Bataillon, Eve Cavaciuti, Dorothée Le Gal, Elodie Girard, Tatiana Popova, Philippe La Rosa, Juana Beauvallet, Séverine Eon-Marchais, Marie-Gabrielle Dondon, Catherine Dubois d'Enghien, Anthony Laugé, Walid Chemlali, Virginie Raynal, Martine Labbé, Ivan Bièche, Sylvain Baulande, Jacques-Olivier Bay, Pascaline Berthet, Olivier Caron, Bruno Buecher, Laurence Faivre, Marc Fresnay, Marion Gauthier-Villars, Paul Gesta, Nicolas Janin, Sophie Lejeune, Christine Maugard, Sébastien Moutton, Laurence Venat-Bouvet, Hélène Zattara, Jean-Pierre Fricker, Laurence Gladieff, Isabelle Coupier, Georgia Chenevix-Trench, Janet Hall, Anne Vincent-Salomon, Dominique Stoppa-Lyonnet, Nadine Andrieu, Fabienne Lesueur
BACKGROUND: The ataxia telangiectasia mutated (ATM) gene is a moderate-risk breast cancer susceptibility gene; germline loss-of-function variants are found in up to 3% of hereditary breast and ovarian cancer (HBOC) families who undergo genetic testing. So far, no clear histopathological and molecular features of breast tumours occurring in ATM deleterious variant carriers have been described, but identification of an ATM-associated tumour signature may help in patient management. METHODS: To characterise hallmarks of ATM-associated tumours, we performed systematic pathology review of tumours from 21 participants from ataxia-telangiectasia families and 18 participants from HBOC families, as well as copy number profiling on a subset of 23 tumours...
April 17, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29665850/common-genetic-variation-and-novel-loci-associated-with-volumetric-mammographic-density
#14
Judith S Brand, Keith Humphreys, Jingmei Li, Robert Karlsson, Per Hall, Kamila Czene
BACKGROUND: Mammographic density (MD) is a strong and heritable intermediate phenotype of breast cancer, but much of its genetic variation remains unexplained. METHODS: We conducted a genetic association study of volumetric MD in a Swedish mammography screening cohort (n = 9498) to identify novel MD loci. Associations with volumetric MD phenotypes (percent dense volume, absolute dense volume, and absolute nondense volume) were estimated using linear regression adjusting for age, body mass index, menopausal status, and six principal components...
April 17, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29661250/isocitrate-dehydrogenase-1-snail-axis-dysfunction-significantly-correlates-with-breast-cancer-prognosis-and-regulates-cell-invasion-ability
#15
Wen-Shan Liu, Shih-Hsuan Chan, Hong-Tai Chang, Guan-Cheng Li, Ya-Ting Tu, Hui-Hwa Tseng, Ting-Ying Fu, Hui-Yu Chang, Huei-Han Liou, Luo-Ping Ger, Kuo-Wang Tsai
BACKGROUND: The isocitrate dehydrogenase (IDH) gene family expresses key functional metabolic enzymes in the Krebs cycle and mediates the epigenetic reprogramming, which serves as an important biomarker of breast cancer. However, the expression levels of the IDH protein and their biological function in human breast cancer remain largely unknown. METHODS: In this study, the clinical impact of IDH1 expression on the progression and prognosis of breast cancer was evaluated using immunohistochemistry assay (IHC) of the corresponding tumor-adjacent normal, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) tissues from 309 patients with breast ductal carcinoma...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29661243/effect-of-neoadjuvant-chemotherapy-regimen-on-relapse-free-survival-among-patients-with-breast-cancer-achieving-a-pathologic-complete-response-an-early-step-in-the-de-escalation-of-neoadjuvant-chemotherapy
#16
Anna Weiss, Sami I Bashour, Kenneth Hess, Alastair M Thompson, Nuhad K Ibrahim
BACKGROUND: Patients with breast cancer who have a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival. We hypothesize that once pCR has been achieved, there is no difference in subsequent postsurgical recurrence-free survival (RFS), whichever NACT regimen is used. METHODS: Data from patients with breast cancer who achieved pCR after NACT between 1996 and 2011 were reviewed. RFS was estimated by the Kaplan-Meier method, and differences between groups were assessed using log-rank testing...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29661221/practice-patterns-and-outcomes-for-patients-with-node-negative-hormone-receptor-positive-breast-cancer-and-intermediate-21-gene-recurrence-scores
#17
Jonathan Chen, Xian Wu, Paul J Christos, Silvia Formenti, Himanshu Nagar
BACKGROUND: The recommendation for chemotherapy in early-stage breast cancer patients has been refined by the 21-gene Recurrence Score. However, uncertainty remains whether patients in the Intermediate Risk category benefit from chemotherapy. METHODS: We analyzed female patients from the National Cancer Database from 2006 to 2012 who had pT1c-T2N0M0 breast cancer, were ER/PR-positive and HER2-negative, received endocrine therapy, and had a 21-gene Recurrence Score from 11 to 25...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29636067/a-novel-neuregulin-jagged1-paracrine-loop-in-breast-cancer-transendothelial-migration
#18
Ramon M Cabrera, Serena P H Mao, Chinmay R Surve, John S Condeelis, Jeffrey E Segall
BACKGROUND: The interaction of breast cancer cells with other cells in the tumor microenvironment plays an important role in metastasis. Invasion and intravasation, two critical steps in the metastatic process, are influenced by these interactions. Macrophages are of particular interest when it comes to studying tumor cell invasiveness. Previous studies have shown that there is paracrine loop signaling between breast cancer cells and macrophages involving colony stimulating factor 1 (CSF-1) produced by tumor cells and epidermal growth factor (EGF) production by macrophages...
April 10, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29566768/functional-genomics-identifies-specific-vulnerabilities-in-pten-deficient-breast-cancer
#19
Yew Chung Tang, Szu-Chi Ho, Elisabeth Tan, Alvin Wei Tian Ng, John R McPherson, Germaine Yen Lin Goh, Bin Tean Teh, Frederic Bard, Steven G Rozen
BACKGROUND: Phosphatase and tensin homolog (PTEN) is one of the most frequently inactivated tumor suppressors in breast cancer. While PTEN itself is not considered a druggable target, PTEN synthetic-sick or synthetic-lethal (PTEN-SSL) genes are potential drug targets in PTEN-deficient breast cancers. Therefore, with the aim of identifying potential targets for precision breast cancer therapy, we sought to discover PTEN-SSL genes present in a broad spectrum of breast cancers. METHODS: To discover broad-spectrum PTEN-SSL genes in breast cancer, we used a multi-step approach that started with (1) a genome-wide short interfering RNA (siRNA) screen of ~ 21,000 genes in a pair of isogenic human mammary epithelial cell lines, followed by (2) a short hairpin RNA (shRNA) screen of ~ 1200 genes focused on hits from the first screen in a panel of 11 breast cancer cell lines; we then determined reproducibility of hits by (3) identification of overlaps between our results and reanalyzed data from 3 independent gene-essentiality screens, and finally, for selected candidate PTEN-SSL genes we (4) confirmed PTEN-SSL activity using either drug sensitivity experiments in a panel of 19 cell lines or mutual exclusivity analysis of publicly available pan-cancer somatic mutation data...
March 22, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29566741/the-amino-acid-transporter-slc7a5-confers-a-poor-prognosis-in-the-highly-proliferative-breast-cancer-subtypes-and-is-a-key-therapeutic-target-in-luminal-b-tumours
#20
Rokaya El Ansari, Madeleine L Craze, Islam Miligy, Maria Diez-Rodriguez, Christopher C Nolan, Ian O Ellis, Emad A Rakha, Andrew R Green
BACKGROUND: Breast cancer (BC) is a heterogeneous disease characterised by variant biology and patient outcome. The amino acid transporter, SLC7A5, plays a role in BC although its impact on patient outcome in different BC subtypes remains to be validated. This study aimed to determine whether the clinicopathological and prognostic value of SLC7A5 is different within the molecular classes of BC. METHODS: SLC7A5 was assessed at the genomic level, using Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) data (n = 1980), and proteomic level, using immunohistochemical analysis and tissue microarray (TMA) (n = 2664; 1110 training and 1554 validation sets) in well-characterised primary BC cohorts...
March 22, 2018: Breast Cancer Research: BCR
journal
journal
34908
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"